No Worsening of Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neurology. Clinical Practice
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS)
Neurol Clin Pract 2023 Oct 01;13(5)e200185, I Kister, C Oh, EA Douglas, TE Bacon, IL O'Shea, EH Parrotta, A Bouley, E Lathi, J KatzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.